The histone deacetylase inhibitor panobinostat as a radiosensitiser in bladder cancer

The histone deacetylase inhibitor panobinostat as a radiosensitiser in bladder cancer

<p>Muscle invasive bladder cancer (MIBC) has a poor prognosis. Currently, therapy consists of radical radiotherapy or cystectomy with or without chemotherapy. The average age of patients with MIBC is high and older patients are less able to tolerate surgery or chemoradiation due to their impai...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Groselj, B
Rannpháirtithe:	Kiltie, A
Formáid:	Tráchtas
Teanga:	English
Foilsithe / Cruthaithe:	2014
Ábhair:	Oncology Biology

Míreanna comhchosúla

Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression
de réir: Groselj, B, et al.
Foilsithe / Cruthaithe: (2013)

Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression.
de réir: Groselj, B, et al.
Foilsithe / Cruthaithe: (2013)

Histone deacetylase inhibitors as radiosensitisers: Effects on DNA damage signalling and repair
de réir: Groselj, B, et al.
Foilsithe / Cruthaithe: (2013)

Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair.
de réir: Groselj, B, et al.
Foilsithe / Cruthaithe: (2013)

Histone Deacetylases and Their Potential as Targets to Enhance Tumour Radiosensitisation
de réir: Jennifer Antrobus, et al.
Foilsithe / Cruthaithe: (2022-03-01)

The histone deacetylase inhibitor romidepsin spares normal tissues while acting as an effective radiosensitiser in bladder tumours in vivo
de réir: Paillas, S, et al.
Foilsithe / Cruthaithe: (2020)

Radiosensitisation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity
de réir: Groselj, B, et al.
Foilsithe / Cruthaithe: (2017)

Identification of novel strategies to radiosensitise tumour cells
de réir: Anbalagan, S
Foilsithe / Cruthaithe: (2014)

Internalising radioimmunoconjugates to target KRas cancer cells for simultaneous radio-ligand therapy and radiosensitisation
de réir: Lourenço, J
Foilsithe / Cruthaithe: (2024)

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
de réir: Lin Xiao, et al.
Foilsithe / Cruthaithe: (2022-05-01)

The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
de réir: Sharma, N, et al.
Foilsithe / Cruthaithe: (2013)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
de réir: Monica Phimmachanh, et al.
Foilsithe / Cruthaithe: (2020-10-01)

The HDAC Inhibitor Panobinostat Promotes Expression of Delta 133p53 Variants in TP53 Wild-type Bladder Cancer Cells
de réir: Groselj, B, et al.
Foilsithe / Cruthaithe: (2012)

Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma
de réir: AGM Mostofa, et al.
Foilsithe / Cruthaithe: (2021-12-01)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
de réir: Masumeh Sanaei, et al.
Foilsithe / Cruthaithe: (2019-01-01)

Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
de réir: Martina Korfei, et al.
Foilsithe / Cruthaithe: (2018-01-01)

Acetylation and Histone Deacetylase Inhibitors in Cancer
de réir: Madeleine S. Q. Kortenhorst, et al.
Foilsithe / Cruthaithe: (2006-01-01)

The Pan-Deacetylase Inhibitor Panobinostat Inhibits Growth of Hepatocellular Carcinoma Models by Alternative Pathways of Apoptosis
de réir: Pietro Di Fazio, et al.
Foilsithe / Cruthaithe: (2010-01-01)

Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines.
de réir: Yukiko Hazama, et al.
Foilsithe / Cruthaithe: (2022-01-01)

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
de réir: Farbod Shojaei, et al.
Foilsithe / Cruthaithe: (2022-01-01)

SET7/9-mediated methylation affects oncogenic functions of histone demethylase JMJD2A
de réir: Ruicai Gu, et al.
Foilsithe / Cruthaithe: (2023-10-01)

Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines
de réir: Zopf Steffen, et al.
Foilsithe / Cruthaithe: (2012-09-01)

Potential of histone deacetylase inhibitors for the therapy of ovarian cancer
de réir: Fengyi Guo, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy
de réir: Bin Tu, et al.
Foilsithe / Cruthaithe: (2020-06-01)

Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer
de réir: Danqi Chen, et al.
Foilsithe / Cruthaithe: (2016-01-01)

Characterisation of the histone acetyltransferase KAT7 as a novel target for radiosensitisation
de réir: Bittner, M
Foilsithe / Cruthaithe: (2017)

The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
de réir: Liebes Leonard, et al.
Foilsithe / Cruthaithe: (2007-10-01)

Histone deacetylase inhibitors in multiple myeloma
de réir: Sarah Deleu, et al.
Foilsithe / Cruthaithe: (2009-06-01)

The application of histone deacetylases inhibitors in glioblastoma
de réir: Rui Chen, et al.
Foilsithe / Cruthaithe: (2020-07-01)

Antidepressant Actions of Histone Deacetylase Inhibitors
de réir: Haggarty, Stephen J., et al.
Foilsithe / Cruthaithe: (2010)

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
de réir: Felix Orben, et al.
Foilsithe / Cruthaithe: (2022-05-01)

Dietary fibre manipulation as a potential endogenous mechanism of radiosensitisation in bladder cancer
de réir: Then, CK
Foilsithe / Cruthaithe: (2022)

Photocaged Histone Deacetylase Inhibitors as Prodrugs in Targeted Cancer Therapy
de réir: Fabian B. Kraft, et al.
Foilsithe / Cruthaithe: (2023-02-01)

p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors
de réir: Eduardo Cepeda Cañedo, et al.
Foilsithe / Cruthaithe: (2021-02-01)

Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models
de réir: Yinglin Wu, et al.
Foilsithe / Cruthaithe: (2022-12-01)

A mitochondrial unfolded protein response inhibitor suppresses prostate cancer growth in mice via HSP60
de réir: Rahul Kumar, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Translational development of MyD88 as a biomarker for selecting patients with lymphoma responsive to histone deacetylase inhibitors
de réir: Sheikh, S
Foilsithe / Cruthaithe: (2017)

Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer
de réir: Ana Vuletić, et al.
Foilsithe / Cruthaithe: (2023-12-01)

Role of histone deacetylases and their inhibitors in neurological diseases
de réir: Li-Ying Zhang, et al.
Foilsithe / Cruthaithe: (2024-10-01)

Histone Deacetylase Inhibitors from Marine Invertebrates
de réir: Claudio Luparello, et al.
Foilsithe / Cruthaithe: (2020-11-01)